Peptide mapping confirms a protein's identity by cutting it into predictable pieces. An enzyme such as trypsin or Lys-C does the cutting. Liquid chromatography separates the pieces, and mass spectrometry usually weighs them. The pattern is then checked against the one expected from the sequence or a reference standard.
- Peptide mapping cuts a protein into predictable fragments with an enzyme and compares them with the expected sequence.
- ICH Q6B lists the peptide map as a structural characterization test frequently used for lot release.
- Trypsin cuts after lysine and arginine; Lys-C cuts after lysine only and gives a simpler pattern.
- LC-MS detection lets each peak be assigned by mass and judged against numeric limits rather than by eye.
- One published method required at least two product-specific identity peptides within plus or minus 0.6 Da.
- The same data can reveal oxidation, deamidation and glycosylation along the chain.
Checking a long sentence in pieces
Suppose you need to confirm that a 450-word paragraph was copied correctly, and you can only read about ten words at a time. You would cut it at every period, check each sentence against the original, and make sure no sentence is missing or changed. Peptide mapping does that to a protein.
A protein is too large to confirm in one measurement with much detail. Its total mass says little about where a single changed residue sits. So the laboratory cuts the protein at known positions with an enzyme, producing a set of shorter peptides whose sequences and masses can be predicted in advance. Each piece is then separated and measured.
If every expected piece shows up at the expected mass, and nothing unexpected appears, the sequence has been checked end to end. If one piece is missing or shifted, the map points to where the difference is.
The research peptide glossary files peptide mapping beside mass spectrometry identity, with a one-sentence definition of each.
- Unfold, reduce and alkylate the protein
- Digest with trypsin or Lys-C
- Separate the fragments on a C18 column
- Weigh each fragment by mass spectrometry
- Match fragments to the expected sequence
How regulators describe it
ICH Q6B, the international guideline on specifications for biotechnological and biological products, lists the peptide map among the tests used to characterize a protein's structure.
It describes the method as selective fragmentation of the product into discrete peptides using suitable enzymes or chemicals, with the fragments then analyzed by HPLC or another appropriate procedure. The fragments should be identified as far as possible, using amino acid composition, N-terminal sequencing or mass spectrometry.
The guideline also notes that peptide mapping with a validated procedure is frequently used to confirm the desired product structure for lot release. So it is a routine identity test for protein products as well as a research technique.
Q6B treats terminal sequence analysis as a separate test, comparing the amino- and carboxy-terminal residues with those expected from the gene sequence. A peptide map covers the interior of the chain that terminal analysis cannot reach.
How is the protein prepared and digested?
The protein is unfolded, its disulfides are broken, and then an enzyme cuts it. A folded protein hides much of its chain from an enzyme, so unfolding comes first. In the 2026 mAbs method, proteins were denatured in 6 M guanidine hydrochloride, then reduced with DTT to break disulfide bonds and alkylated with iodoacetic acid so those bonds cannot re-form.
Then comes the enzyme. The two most common choices cut at predictable residues:
| Enzyme | Cuts after | Result |
|---|---|---|
| Trypsin | Lysine and arginine | Many short peptides |
| Endoproteinase Lys-C | Lysine only | Fewer, longer peptides; a simpler pattern |
The mAbs authors chose Lys-C because it gave a simpler peptide pattern than trypsin, digesting at an enzyme to protein ratio of 1 to 100 by mass for 2 hours at 45 degrees Celsius. Because the cut sites are known, the full list of expected peptides can be calculated from the sequence before the experiment starts.
Step two: separate and measure
The digest is a mixture of dozens of peptides. Reversed-phase liquid chromatography spreads them out in time, each peptide leaving the column at its own retention time according to how hydrophobic it is. A peptide rich in nonpolar side chains holds on longer; a short, charged one comes off early. The same digest run on the same column gives the same order of peaks, which is what makes a map comparable from lot to lot. The mAbs method used a C18 column, the standard choice for peptides.
Older peptide maps stopped there and read the result with a UV detector: the chromatogram's pattern of peaks was compared by eye with a reference standard run alongside. The weakness is that UV patterns are complex and shift from run to run, with retention times drifting and resolution changing, so a visual comparison is partly a judgment call.
Adding a mass spectrometer after the column changes the question from what the pattern looks like to what each peak weighs. Every peak can be assigned to a specific peptide by mass, and the comparison can be run by software against numeric limits. How that mass measurement works is covered in our guide to LC-MS peptide identity testing.
Step three: compare and decide
A peptide map passes when the expected peptides are found where they should be. The mAbs paper shows how that decision can be made without a human reading a chart.
Its authors first picked identity peptides: fragments that an in silico digest predicted would be unique to one product, then confirmed by high-resolution tandem mass spectrometry, then checked against data for every other product in their portfolio of about 120 biologics to make sure no other product produced them. Each product needed at least two such peptides.
A sample then passes only when each identity peptide appears within its expected retention time window, within a mass tolerance of plus or minus 0.6 daltons, and above a minimum signal intensity. All three limits are numbers, so two analysts looking at the same data reach the same answer.
What else can a peptide map show?
A peptide map can also show small chemical changes such as oxidation or deamidation. Because every fragment is weighed, the same data can reveal small chemical changes along the chain. A fragment carrying an oxidized methionine weighs about 16 daltons more than expected. A deamidated asparagine or glutamine shifts it by about 1 dalton. Glycosylation adds much more.
The mAbs authors list N-glycosylation, oxidation, deamidation, isomerization and glycation among the variants an LC-MS peptide map can evaluate. Extending the identity test to measure those variants is what the field calls a multi-attribute method, though the paper notes that quantitative use needs its own validation beyond identity.
This is where peptide mapping differs from a purity test. HPLC purity reports how much of the sample sits in the main peak. A peptide map reports whether the chain in that peak has the right sequence and where it has been modified. Our guide to HPLC purity versus identity explains why a certificate needs both kinds of result.
Reading a peptide map report
A peptide map result on a certificate or a characterization report should let a reader rebuild what was done. At a minimum, look for these details.
- The enzyme or chemical used to cut the protein, and the digestion conditions: ratio, time and temperature.
- Whether the protein was denatured, reduced and alkylated first, since a folded protein may leave parts of its chain uncut.
- The separation: column type and gradient.
- The detection method, UV alone or mass spectrometry.
- What the result was compared against, either a reference standard run alongside or the sequence-predicted list of fragments.
- The acceptance limits: which peptides had to be found, the retention time windows and the mass tolerance.
A report that says only "peptide map conforms" gives none of that. It may well be true, but the reader cannot check it. ICH Q6B frames the map as one test among several in a structural characterization, so a report that pairs it with intact mass and terminal sequence analysis gives the fullest picture of a protein's identity.
When is a peptide map needed?
A peptide map is needed mainly for large molecules such as proteins. A protein of several hundred residues can carry a single substitution that barely moves the total mass, and a map is the practical way to find it.
Short synthetic peptides are a different case. An eight- or fifteen-residue peptide is already about the size of one mapping fragment. Its intact mass can be measured directly, and tandem mass spectrometry can fragment it to read the sequence, so cutting it with an enzyme first adds little. Identity for a short research peptide usually rests on intact mass plus fragmentation, with HPLC for purity.
For larger research proteins, and for anything built on an antibody or fusion-protein scaffold, a certificate that reports only an intact mass has skipped the step that checks the interior of the chain. It is fair to ask whether a peptide map was run and which enzyme was used.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Common questions
What is peptide mapping used for?
Why use Lys-C instead of trypsin?
Is a peptide map the same as HPLC purity?
Do short research peptides need peptide mapping?
Peptide mapping, in one sentence?
More science guides
Sources
- ICH Q6B, Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Describes the peptide map as selective fragmentation with enzymes or chemicals followed by HPLC or other analysis, and its frequent use to confirm structure for lot release; terminal sequence analysis as a separate test.
- Using mass spectrometry for robust identity release testing in a global quality control network, mAbs, 2026. Denaturation, reduction and alkylation; Lys-C versus trypsin; digestion conditions; C18 separation; product-specific identity peptides, the plus or minus 0.6 Da tolerance and the limits of UV pattern comparison; modifications visible by LC-MS.
- FDA guidance, Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. FDA's adoption of the ICH Q6B guideline, August 1999.
